drugset / Trial / NCT01724918
Lacosamide IV and EEG/EKG (LIVE) Study
Phase 2
Terminated
72 enrolled
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
UCB Pharma · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to evaluate the effect of different intravenous doses (IV) of a new anti-epileptic drug (AED) called lacosamide on continuous EEG (electroencephalogram) rhythms (or brain rhythms) in subjects with focal seizures and the tolerability of those doses by patients. In addition, this study will assess the effect of IV lacosamide on EKG (electrocardiogram), a test which checks for problems with the electrical activity of the heart.
Timeline
- Start
- 2013-05
- Primary completion
- 2016-08
- Completion
- 2016-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lacosamide | Other / unclassified | 100 mg | Intravenous |
| Subject | Lacosamide | Other / unclassified | 200 mg | Intravenous |
| Subject | Lacosamide | Other / unclassified | 400 mg | Intravenous |